Taysha Gene Therapies Financials - Benzinga

Taysha Gene Therapies Inc

TSHANASDAQ

Trade with Public

Trade with Public

$6.34

-0.12-1.86%

At close: Aug 5, 5:00 PM EST

$6.46

N/A

Pre-Market: 6:42 AM EST

Earnings: Q2 2026 Earnings in 4 days from now on Tue Aug 11th, after the market close

Conference Call: Conference call scheduled in 4 days at 4:30 PM

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Taysha Gene Therapies Financials

Taysha Gene Therapies (TSHA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Taysha Gene Therapies Q1 EPS $(0.12) Misses $(0.10) Estimate

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 50 percent decrease over losses of $(0.08) per share from

Benzinga Newsdesk

PRO
Taysha Gene Therapies Q4 EPS $(0.12) Misses $(0.10) Estimate, Sales $5.485M Beat $1.889M Estimate.

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 23.71 percent. This is a 71.43 percent decrease over losses of $(0.07) per

Benzinga Newsdesk

Earnings Scheduled For March 19, 2026

Benzinga Insights

PRO
Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0. Cash And Equivalents $299.94M.

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the same period last year.

Benzinga Newsdesk

Earnings Scheduled For November 4, 2025

Benzinga Insights